152 related articles for article (PubMed ID: 22713338)
1. Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.
Bowker KE; Noel AR; Tomaselli SG; Elliott H; Macgowan AP
Antimicrob Agents Chemother; 2012 Oct; 56(10):5009-15. PubMed ID: 22713338
[TBL] [Abstract][Full Text] [Related]
2. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.
Kim A; Banevicius MA; Nicolau DP
Antimicrob Agents Chemother; 2008 Jul; 52(7):2497-502. PubMed ID: 18458125
[TBL] [Abstract][Full Text] [Related]
3. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Efficacy of Doripenem against Pseudomonas aeruginosa and Acinetobacter baumannii by E-Test.
Gilani M; Munir T; Latif M; Rehman S; Ansari M; Hafeez A; Najeeb S; Saad N; Gilani M
J Coll Physicians Surg Pak; 2015 Oct; 25(10):726-9. PubMed ID: 26454387
[TBL] [Abstract][Full Text] [Related]
5. Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
Pankuch GA; Seifert H; Appelbaum PC
Diagn Microbiol Infect Dis; 2010 Jun; 67(2):191-7. PubMed ID: 20338710
[TBL] [Abstract][Full Text] [Related]
6. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model.
Firsov AA; Gilbert D; Greer K; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2012 Mar; 56(3):1223-8. PubMed ID: 22203591
[TBL] [Abstract][Full Text] [Related]
8. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
Goyal K; Gautam V; Ray P
Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
[TBL] [Abstract][Full Text] [Related]
9. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
Housman ST; Hagihara M; Nicolau DP; Kuti JL
J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
[TBL] [Abstract][Full Text] [Related]
10. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Jacob J; Sidjabat HE; Paterson DL; Nation RL; Li J
Antimicrob Agents Chemother; 2011 Dec; 55(12):5685-95. PubMed ID: 21911563
[TBL] [Abstract][Full Text] [Related]
11. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.
Rao GG; Ly NS; Bulitta JB; Soon RL; San Roman MD; Holden PN; Landersdorfer CB; Nation RL; Li J; Forrest A; Tsuji BT
J Antimicrob Chemother; 2016 Nov; 71(11):3148-3156. PubMed ID: 27494922
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development.
Tam VH; Ledesma KR; Vo G; Kabbara S; Lim TP; Nikolaou M
Antimicrob Agents Chemother; 2008 Nov; 52(11):3987-93. PubMed ID: 18725438
[TBL] [Abstract][Full Text] [Related]
13. Highly Synergistic Effects of Melittin with Conventional Antibiotics Against Multidrug-Resistant Isolates of Acinetobacter baumannii and Pseudomonas aeruginosa.
Akbari R; Hakemi-Vala M; Pashaie F; Bevalian P; Hashemi A; Pooshang Bagheri K
Microb Drug Resist; 2019 Mar; 25(2):193-202. PubMed ID: 30281385
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
Abdul-Aziz MH; Abd Rahman AN; Mat-Nor MB; Sulaiman H; Wallis SC; Lipman J; Roberts JA; Staatz CE
Antimicrob Agents Chemother; 2016 Jan; 60(1):206-14. PubMed ID: 26482304
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
Biedenbach DJ; Giao PT; Hung Van P; Su Minh Tuyet N; Thi Thanh Nga T; Phuong DM; Vu Trung N; Badal RE
Clin Ther; 2016 Sep; 38(9):2098-105. PubMed ID: 27612610
[TBL] [Abstract][Full Text] [Related]
16. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.
Cheah SE; Wang J; Nguyen VT; Turnidge JD; Li J; Nation RL
J Antimicrob Chemother; 2015 Dec; 70(12):3291-7. PubMed ID: 26318190
[TBL] [Abstract][Full Text] [Related]
17. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
Louie A; Bied A; Fregeau C; Van Scoy B; Brown D; Liu W; Bush K; Queenan AM; Morrow B; Khashab M; Kahn JB; Nicholson S; Kulawy R; Drusano GL
Antimicrob Agents Chemother; 2010 Jun; 54(6):2638-45. PubMed ID: 20308371
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility patterns of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline.
Somily AM; Absar MM; Arshad MZ; Al Aska AI; Shakoor ZA; Fatani AJ; Siddiqui YM; Murray TS
Saudi Med J; 2012 Jul; 33(7):750-5. PubMed ID: 22821309
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
Crandon JL; Bulik CC; Nicolau DP
Antimicrob Agents Chemother; 2009 Oct; 53(10):4352-6. PubMed ID: 19770286
[TBL] [Abstract][Full Text] [Related]
20. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
